Saphris

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2015
01220092015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
OBJECTIVE To assess clinical features of therapeutic efficacy and tolerability of asenapine (saphris) in stopping acute psychotic… (More)
Is this relevant?
Review
2015
Review
2015
The causes and origins of pica remain unknown and are the source of speculation and heated debate. Bariatric surgery patients are… (More)
Is this relevant?
Review
2011
Review
2011
The second generation atypical antipsychotic, asenapine (Saphris), was approved by the US FDA (August 2009) for the acute… (More)
Is this relevant?
Review
2011
Review
2011
“black-box” warnings for all antipsychotic drugs.2 Antipsychotic agents may be classified in several ways. Commonly, they can be… (More)
  • table 1
Is this relevant?
2010
2010
On August 14th, 2009, for the first time, the FDA has approved a psychotropic medication for two indications simultaneously… (More)
Is this relevant?
Review
2010
Review
2010
In this article we investigate the post-launch retail prescription trends of asenapine (Saphris(®), Merck and Co.) and… (More)
Is this relevant?
2010
2010
  • JAAPA : official journal of the American Academy…
  • 2010
 
Is this relevant?
Review
2010
Review
2010
  • 2010
According to a Medical Letter review of the recently approved atypical antipsychotic asenapine (Saphris), "available data on its… (More)
Is this relevant?
Review
2010
Review
2010
  • The Medical letter on drugs and therapeutics
  • 2010
 
Is this relevant?
2009
2009
In August 2009, asenapine (Saphris; Schering–Plough) was approved by the US FDA for the acute treatment of schizophrenia and… (More)
  • figure 1
Is this relevant?